Wales is a self-governing country of the UK and the Welsh Government is the devolved Government for Wales. The Welsh Government’s decision-making powers within a small and joined-up country mean we can act fast. They also mean we are responsible for our own economic development, so you won’t find a more pro-business Government anywhere. Wales has a strong industrial heritage that has shaped our confident, creative and ambitious economy of today. Wales means business.
UNLV Office of Technology Transfer and Economic Development
UNLV is Nevada’s premier public research university and a powerhouse for groundbreaking discovery and innovation, particularly in life sciences and biotechnology. At the forefront of UNLV’s industry and business engagement are our dynamic offices of Economic Development and Technology Transfer, serving as vital connectors between pioneering research and impactful commercialization opportunities. UNLV’s cutting-edge Brain Health Department as well as the innovative Wastewater Surveillance Laboratory exemplify our bold approach to solving complex health and environmental challenges. Researchers at these centers drive groundbreaking advancements with profound implications for neuroscience, public health, environmental monitoring, and disease prevention. Uniquely situated within a collaborative and vibrant regional ecosystem, UNLV thrives alongside major stakeholders committed to ambitious, strategic coordination and innovative thinking. This environment enables business and industry partnerships to flourish, supported by open communication and outside-the-box planning that accelerate shared success. At BIO International 2025, our goal is clear: to connect industry leaders, visionaries, and partners directly with UNLV’s exceptional talent, transformative research capabilities, and rich pipeline of licensable technologies. Opportunities abound at UNLV for collaborative sponsored research, tailored workforce development programs, robust startup incubation support, and access to patented university technologies poised for commercialization. Discover how partnering with UNLV can propel your organization’s priorities forward through innovative solutions and collaborations. Connect with us at BIO to harness the full potential of our research excellence and vibrant innovation ecosystem. | UNLV, a Carnegie R1 research institution, is a key player in the delegation’s efforts. UNLV emphasizes industry engagement through opportunities for students, strong bio research, innovation, a collaborative research and technology park, and commercialization of life-changing products in fields like life science, physical science, and engineering. UNLV is seeking to connect with BIOtech companies and explore collaboration opportunities.
University of Maryland BioPark
The University of Maryland BioPark is Baltimore’s largest biotech cluster and a cornerstone of the region’s welcoming, collaborative, and tight-knit innovation community. Positioned in the heart of the Mid-Atlantic’s life science corridor, we deliver Maryland’s world-class workforce and unparalleled access to prestigious academic and medical institutions, the nation’s capital, and regulatory and governing institutions. The BioPark is home to a mix of life science and technology companies at all sizes and stages – leading global firms, early-stage ventures, university spinouts, distinguished research organizations, cutting-edge clinical care, and contemporary workforce training programs. Our companies are applying novel approaches to advance solutions to challenging health problems. Located on the campus of the University of Maryland, Baltimore (UMB) – a thriving academic health center combining cutting-edge biomedical research and exceptional patient care – the BioPark places the power of the University of Maryland’s research enterprise and clinical care at your doorstep, fostering connections that advance your ventures. The University of Maryland’s joint research enterprise received $1.3 billion in research awards in FY2025 and was ranked 9th among all public U.S. research institution sin the National Science Foundation’s FY2024 Higher Education Research and Development survey. Each year, UMB conducts over $70 million in corporate-sponsored research annually and, at the present time, the University is working with more than 300 bioscience and pharmaceutical firms. UMB’s largest school, the University of Maryland School of Medicine (UMSOM), is known for pioneering new treatments in many areas of strength, which include transplant science, infectious disease, cancer care, and shock trauma. Other important areas of clinical strength include radiation oncology, focused ultrasound, orthopaedic trauma, population health, genomics, and cardiology. In FY2025, UMSOM received $514 million in research funding and was ranked 9th for Total Research Funding by the Association of American Medical College’s most recent ranking. Learn more about UMB at www.umaryland.edu.
The National Institute for Health and Care Research (NIHR)
The NIHR Life Sciences Industry Hub is your entry point to England’s integrated clinical research system, with coordinated access to UK-wide capability. The Industry Hub’s support is free of charge, funded by the UK Government, and designed to make the UK a globally competitive destination for commercial clinical research. We provide: Single national entry to NIHR – One conversation provides access to our entire integrated commercial trials pathway. Dedicated operational leadership – A named national lead coordinates delivery and manages dependencies across the system. Reliable, data-enabled feasibility – Coordinated once, using real-time capability and capacity to improve predictability. Smarter site selection – Intelligent study placement across health and care settings for speed, quality and performance. Faster start-up – Coordinated oversight of costing, contracting and assurance. Active performance management and escalation – Real-time oversight of set-up and recruitment, with clear escalation routes and time-bound resolution. Inclusive, scalable recruitment – Approaches that improve reach, diversity and reliability, including digitally-enabled and hybrid delivery models. Strategic partnership opportunities – Portfolio-level engagement and longer-term collaboration with the NIHR research system.
The Hong Kong Polytechnic University
With 85 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. Our holistic professional education, which embraces new technologies, entrepreneurship, and service-learning, aims to nurture graduates who not only possess a competitive edge in their disciplinary knowledge, but also develop into socially responsible leaders. As a university with a strong emphasis on societal impact, PolyU is devoted to providing interdisciplinary solutions for major social challenges through advanced research and knowledge transfer activities. Our innovations have opened up new horizons in space, improved health and well-being, boosted economic efficiency, and fostered sustainability for a better world. Our strong culture of knowledge transfer and entrepreneurship helps transform our research breakthroughs into real-world applications. Looking to the future, PolyU will continue its pursuit of excellence, cultivating talent who serve society with passion, and contributing to the development of Hong Kong as an international innovation and technology hub in the Greater Bay Area. We will carry on manifesting the spirit of the University’s Motto: To learn and to apply, for the benefit of mankind. | With 86 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. Our holistic professional education, which embraces new technologies, entrepreneurship, and service-learning, aims to nurture graduates who not only possess a competitive edge in their disciplinary knowledge, but also develop into socially responsible leaders. As a university with a strong emphasis on societal impact, PolyU is devoted to providing interdisciplinary solutions for major social challenges through advanced research and knowledge transfer activities. Our innovations have opened up new horizons in space, improved health and well-being, boosted economic efficiency, and fostered sustainability for a better world. Our strong culture of knowledge transfer and entrepreneurship helps transform our research breakthroughs into real-world applications. Looking to the future, PolyU will continue its pursuit of excellence, cultivating talent who serve society with passion, and contributing to the development of Hong Kong as an international innovation and technology hub in the Greater Bay Area. We will carry on manifesting the spirit of the University’s Motto: To learn and to apply, for the benefit of mankind. | The Hong Kong Polytechnic University (PolyU) aspires to be an innovative world-class university that pursues excellence in education, research and knowledge transfer. Driven by its motto, “To learn and to apply, for the benefit of mankind”, the University nurtures socially responsible professionals and leaders and pursues world-leading research and innovation for societal benefits. | With 85 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. We strive in inter-disciplinary research and impactful innovations to address real-world challenges.
Taiwan Contract Research One-Stop Service
(1) To establish a leading preclinical R&D alliance in Taiwan. (2) To integrate the core strengths of five major R&D institutions in Taiwan: National Center for Biomodels (NCB) of the National Institutes of Applied Research, Biomedical Translation Research Center of Academia Sinica, Industrial Technology Research Institute (ITRI), Development Center for Biotechnology (DCB), and National Health Research Institutes. (3) To provide a complete one-stop CRO service, accelerating the translation and industrialization of innovative achievements in biotechnology and medicine.
TaiMed Biologics
TaiMed Biologics, founded in 2007, is a leading biopharmaceutical developer and manufacturer in Taiwan. We have extensive monoclonal antibodies (mAb) development and manufacturing experiences and have successfully developed and commercially launched the first and only mAb for HIV treatment in the US and Europe (Brand name: Trogarzo®). We are proud to offer Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies to propel your important monoclonal antibody molecules from development to market launch. | TaiMed Biologics & Orient EuroPharma — Your Trusted Partners in Biologics and CDMO Services TaiMed Biologics (TaiMed) is a leading biopharmaceutical company specializing in the development and manufacturing of innovative biologics, with a strong focus on anti-HIV therapies. Our Key Strengths Include: – First-in-Class Innovation: Developer of Trogarzo® (ibalizumab), the world’s first long-acting monoclonal antibody for HIV, approved by the US FDA and EMA in 2018 and 2019. – Next-Gen HIV Therapies: Advancing long-acting monoclonal antibodies for HIV treatment and prevention. – Clinical-Stage Leadership: Leading candidate TMB-365/380 received Fast Track Designation from the US FDA in 2023 and has successfully completed Phase 2a, showing promising potential as a more confirming and durable HIV therapy. – Partnering Opportunities: Actively seeking global licensing and co-development partnerships with companies focused on HIV therapy. – CDMO Services: Leveraging decades of antibody development experience, TaiMed now offers end-to-end CDMO solutions, from early-stage development through to commercial manufacturing. This year, TaiMed is proud to co-exhibit with our long-term partner, Orient EuroPharma (OEP), to present integrated, high-quality biomanufacturing solutions that meet global standards. About Orient EuroPharma (OEP) Founded in 1982, Orient EuroPharma (OEP) is a Taiwan-based multinational pharmaceutical company specializing in prescription medicines, nutricare, and anti-aging products. OEP also offers comprehensive CDMO services, providing expertise from formulation development to commercial-scale finished product manufacturing. OEP’s CDMO capabilities include: – Formulation Development: Expertise in controlled-release formulations – Oral Dosage Manufacturing: Tablet, Capsule (granule/pellets/semi-solid/liquid filling) – Injectable Manufacturing: Liquid and lyophilized vials for high potency, cytotoxic and non-cytotoxic product Why Partner with OEP? – Regulatory Excellence: 15+ successful IND submissions in the U.S., China, and Taiwan; NDA projects ongoing – U.S.-Based R&D (San Diego Lab): Local formulation development & small-scale batch production for faster collaboration – Advanced Capsule Technology: Specialized in semisolid/liquid filling and banding for enhanced drug stability -Flexible Manufacturing Scale: Seamless transition from small-batch IND to large-scale NDA production – Quality Certification: Facilities certified by US FDA, PIC/S GMP, TGA, and MHRA With a strong track record of innovation, regulatory success, and manufacturing quality, TaiMed and OEP together offer a powerful CDMO partnership to support your drug development and commercialization goals. Visit us at our booth to explore collaborative opportunities!
Swiss Business Hub USA
The Swiss Business Hub USA is the New York-based representative of the official international trade and investment promotion agency Switzerland Global Enterprise (S-GE). Part of the Consulate General of Switzerland in New York and with offices in San Francisco, Atlanta and Boston (Cambridge), it is responsible for implementing Swiss export strategies in the US and for promoting Switzerland as a business location. The Swiss Business Hub USA provides localized support, market information, consulting and networking services to Swiss companies venturing into the US market. In addition, the Swiss Business Hub actively promotes Switzerland as a highly attractive business and investment location for US companies looking for growth in Switzerland and in Europe. The Swiss Business Hub proactively contacts and informs US-based companies about the key advantages of Switzerland as a business and investment location. The Swiss Business Hub USA has a first-rate network of contacts both in the US and in Switzerland. | The Swiss Business Hub USA is the New York-based representative of the official international trade and investment promotion agency Switzerland Global Enterprise (S-GE). Part of the Consulate General of Switzerland in New York and with offices in San Francisco, Atlanta and Boston (Cambridge), it is responsible for implementing Swiss export strategies in the US and for promoting Switzerland as a business location.
Seoul Bio hub
Seoul Bio Hub, located in northern Seoul and opened in October 2017, is a life science innovation center sponsored by the Seoul Metropolitan Government and operated by Korea Institute of Science and Technology(KIST) and Korea University(KU). The key function is to support early stage life science companies’ growth and commercialization by providing full service wet laboratory and office spaces, shared equipment, networking events, training programs, and investor relation opportunities. As the only biotech startup platform located in Seoul, it leverages its geographical advantages to accelerate the startup ecosystem, by facilitating cooperative networks among research-driven hospitals, universities, national research institutes, and venture capitals within close vicinity.
Seoul National University Hospital (SNUH)
Seoul National University Hospital (SNUH) is South Korea’s leading medical institution, renowned for excellence in patient care, medical research, and education. Established in 1885, SNUH has played a pivotal role in advancing healthcare and medical sciences in the country. SNUH is dedicated to pioneering medical research, contributing to global medical advancements through innovative treatments and clinical trials. The hospital also plays a crucial role in training future medical professionals, fostering excellence in both academic and practical medical education. With a commitment to patient-centered care, SNUH continues to provide high-quality medical services, ensuring the well-being of patients from Korea and around the world. Seoul National University Hospital was designated as the 1st National Strategic Technology Research Institute (NSTRI) from the ministry of Healthcare and Welfare of Korean government. NSTRI is designated to perform crucial functions for the stable and strategic development of advanced bio-technologies. The institute operates with three key focus areas: 1) the development of an “advanced bio-research data platform,” 2) the establishment of a “digital bio international cooperation ecosystem,” 3) the cultivation of “core talent in physician-scientists.” For more information, please visit here 🙂 http://www.snuh.org/english https://nstri-en.snuh.org